Healthcare Industry News: Merlin@home
News Release - August 31, 2011
St. Jude Medical Begins U.S. Trial Studying ST Segment Monitoring TechnologyAnalyze ST trial will evaluate safety and efficacy of ST segment monitoring in Fortify ST ICD
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)-- St. Jude Medical, Inc. (NYSE:STJ ), a global medical device company, today announced that the first patient in a clinical study examining the safety and effectiveness of an ST segment monitoring feature in an implantable cardioverter defibrillator (ICD) has been implanted with the investigational device in the United States. The ST Monitoring to Detect ACS Events in ICD Patients (Analyze ST) study will evaluate effectiveness of the feature in the Fortify® ST ICD by analyzing its accuracy in detecting acute coronary events, such as myocardial infarction, commonly known as a heart attack.
Dr. Scott Allison and Dr. Paul B. Tabereaux of Heart Center, Inc. at Huntsville Hospital in Alabama implanted the first two patients in the trial. Commenting on the study, Dr. Allison said, “When a patient is experiencing a heart attack, every minute counts. For every 30 minutes that treatment is delayed, mortality increases by 7.5 percent. Because symptoms can be vague, and approximately one-third of patients don’t even have typical chest symptoms, the average time it takes for a patient to seek treatment has remained at almost 3 hours over the last decade. We hope the device being studied in the Analyze ST trial can help provide physicians with more information about coronary events that will allow us to intervene and provide treatment earlier.”
The ST segment is a section of an electrocardiogram (ECG) that depicts electrical changes between heartbeats. Changes in ST segments have long been studied in clinical settings using external devices as indicators for an obstruction of blood flow and oxygen to the heart muscle (cardiac ischemia). However, due to several limitations, it has not been practical to study them on a continual basis. A method to monitor the ST segment without such limitations could provide important insights into the overall clinical assessment of patients at risk for coronary events. Monitoring for ST changes within the heart of an ambulatory patient may provide unique insight into the presence and severity of changes of the ST segment and occurrence of ischemia in patients with coronary artery disease (CAD).
The Analyze ST trial is a prospective, non-randomized, multicenter, pivotal IDE investigation of up to 5,228 patients at approximately 200 medical centers. St. Jude Medical received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to study the safety and efficacy of the ST segment monitoring feature in the Fortify ST ICD. The sensitivity of the feature for detecting acute coronary syndrome events will be the primary efficacy endpoint. The primary safety endpoint will be assessed by reporting the percentage of patients who experience a false positive detection.
“We know that ST segment changes can help us to identify CAD events, so the continuous, internal monitoring that is possible with this technology could provide physicians with an early warning signal that a patient is experiencing an ischemic event,” said Dr. Mark Carlson, chief medical officer and senior vice president of research and clinical affairs for the St. Jude Medical Cardiac Rhythm Management Division. “Since many patients do not experience symptoms during a heart attack, this technology has the potential to improve the diagnosis and treatment of cardiac ischemia.”
More than half of patients experiencing a heart attack die before reaching a hospital. Even patients with stable CAD are at high risk of having a life-threatening or potentially fatal coronary event. Additionally, 15 to 20 percent of patients who have had an ischemic event have recurrent events. As a result, CAD needs to be managed on an ongoing basis to avoid a more unstable or life threatening acute coronary event. Furthermore, approximately two-thirds of ICD patients have cardiac ischemia, with many more having risk factors for developing cardiovascular disease.
During ST segment shifts, the ICD records high-resolution electrograms that can then be transmitted, along with additional information, for download into the Merlin™ Patient Care System in the clinic, or to the Merlin.net™ Patient Care Network from the patient’s home via a Merlin@home™ transmitter. During the course of the study, the device’s patient alert feature will also be turned on, which would notify the patient via a vibratory alert when an ST segment change occurs.
Based on the Fortify platform, the Fortify ST ICD features advanced battery technology and circuitry that allow for a smaller device, the highest energy output delivery (40J) of any ICD, as well as rapid charge times, all while increasing device longevity. The devices’ narrow shape, along with their small footprint, allows physicians to implant them using a smaller incision, leading to less time spent closing the incision and a reduced scar for the patient.
The ST Monitoring Feature has received European CE Mark approval and has been used in St. Jude Medical ICDs since December 2008. The most recently CE Mark approved model is the Fortify ST ICD.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2011. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Source: St. Jude Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.